How to Get the Wegovy Pill (or Why You Probably Mean Rybelsus): The Complete Access Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy exists only as a weekly injection, not a pill; the oral semaglutide pill is called Rybelsus and is FDA-approved only for type 2 diabetes, not weight loss
• Getting either requires a prescription from a licensed provider, which you can obtain through in-person visits, telehealth platforms, or digital health services like FormBlends
• Insurance coverage for Wegovy averages 40% approval rate for weight loss; Rybelsus for weight loss is rarely covered because it's off-label
• Compounded oral semaglutide (available through platforms like FormBlends) offers an alternative path when brand-name options are unavailable or unaffordable, typically $297-$397 per month

Direct answer (40-60 words)

Wegovy is not available as a pill. It exists only as a weekly subcutaneous injection. The oral semaglutide medication is Rybelsus, FDA-approved for type 2 diabetes but prescribed off-label for weight loss. Both require a prescription from a licensed provider. Access routes include traditional healthcare, telehealth platforms, or compounded alternatives through specialized pharmacies.

Table of contents

1. What most articles get wrong about "Wegovy pill"
2. The two semaglutide products: injection vs oral
3. The prescription requirement: what providers evaluate
4. The five pathways to get a prescription
5. Insurance coverage: approval rates and appeal strategies
6. The out-of-pocket cost comparison
7. Compounded semaglutide: when and why it's the practical choice
8. The oral vs injectable decision tree
9. Supply constraints and the FDA shortage list
10. State-by-state telehealth restrictions that affect access
11. When you should NOT pursue semaglutide
12. FAQ

What most articles get wrong about "Wegovy pill"

The search query "how to get the wegovy pill" reflects a widespread misconception that Novo Nordisk makes an oral version of Wegovy. They don't. The confusion stems from three sources:

1. Brand name overlap. Both Wegovy and Rybelsus contain semaglutide. Wegovy is the 2.4 mg weekly injection for weight loss. Rybelsus is the daily oral tablet (3 mg, 7 mg, or 14 mg) for type 2 diabetes.

1. Off-label prescribing. Providers prescribe Rybelsus off-label for weight loss, which creates the impression that it's "the Wegovy pill." It's not. The FDA has never approved oral semaglutide for obesity.

1. Compounded oral semaglutide marketing. Compounding pharmacies produce oral semaglutide capsules or sublingual formulations, sometimes marketed as "oral Wegovy alternative." These are not Wegovy, not Rybelsus, and not FDA-approved.

The practical consequence: if you want a pill, you're asking for Rybelsus (off-label) or compounded oral semaglutide. If you want FDA-approved semaglutide for weight loss, you're getting an injection.

Most published content conflates these products or fails to explain why oral semaglutide has lower efficacy than injectable. The bioavailability difference is the reason the FDA approved them for different indications.

The two semaglutide products: injection vs injectable

Feature	Wegovy (injection)	Rybelsus (oral tablet)
Active ingredient	Semaglutide	Semaglutide
FDA approval	Chronic weight management (2021)	Type 2 diabetes only (2019)
Dosing	Once weekly subcutaneous	Once daily oral, fasting required
Maintenance dose	2.4 mg/week	14 mg/day (max approved dose)
Bioavailability	~80-90%	~1% (absorption enhancer required)
Average weight loss (68 weeks)	14.9% body weight (STEP 1)	3.7% body weight at 14 mg (PIONEER 1)
Nausea rate	44% (STEP 1)	11-20% depending on dose (PIONEER trials)
Insurance coverage for weight loss	~40% approval	Rare (off-label)
List price (2026)	$1,349/month	$969/month

The bioavailability gap is the critical difference. Oral semaglutide requires a permeation enhancer (SNAC, sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to survive stomach acid and cross the intestinal wall. Even with SNAC, only about 1% of the dose reaches circulation compared to 80-90% with injection (Buckley et al., Clinical Pharmacokinetics, 2018).

To compensate, Rybelsus uses daily dosing instead of weekly. The 14 mg daily dose delivers roughly equivalent steady-state exposure to 0.5 mg weekly injectable semaglutide, which is the starting dose of Wegovy, not the maintenance dose. This is why PIONEER trial weight loss averaged 3.7% vs 14.9% in STEP 1.

The prescription requirement: what providers evaluate

Both Wegovy and Rybelsus are prescription-only medications. The FDA requires provider evaluation of:

Medical eligibility criteria:

• BMI 30 or greater, OR
• BMI 27 or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Age 18 or older (pediatric approval exists for Wegovy ages 12+ but not Rybelsus)

Contraindications that disqualify you:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Pregnancy or breastfeeding
• History of severe hypersensitivity to semaglutide
• History of pancreatitis (relative contraindication, provider discretion)
• Diabetic retinopathy (requires ophthalmology clearance)

Labs most providers order before prescribing:

• Comprehensive metabolic panel (kidney and liver function)
• Lipid panel
• Hemoglobin A1c (to screen for undiagnosed diabetes)
• TSH (thyroid function)
• Pregnancy test for anyone with childbearing potential

The evaluation can happen in person or via telehealth. Most platforms require a video visit for initial prescriptions, though some accept asynchronous (questionnaire-based) evaluations for straightforward cases.

The provider is evaluating two questions: (1) Is this medication safe for you? (2) Is this medication appropriate for your clinical situation? A BMI of 29 with no comorbidities fails the appropriateness test even though it's medically safe.

The five pathways to get a prescription

Pathway 1: Primary care provider or endocrinologist.

Your existing provider can prescribe either Wegovy or Rybelsus. The advantage is continuity of care and integration with your medical record. The disadvantage is that many primary care offices are unfamiliar with GLP-1 weight management protocols, leading to conservative dosing or reluctance to prescribe off-label.

Typical timeline: 1 to 2 weeks from request to prescription, assuming labs are current.

Pathway 2: Weight management clinic.

Specialized obesity medicine clinics (hospital-affiliated or private) focus exclusively on weight management. Providers are experienced with GLP-1 medications and comfortable with off-label prescribing.

Typical timeline: 2 to 4 weeks for initial consultation. Often requires in-person visits.

Pathway 3: Telehealth platforms (Ro, Hims, Henry Meds, others).

Direct-to-consumer telehealth platforms connect you with licensed providers via video or asynchronous questionnaire. Most offer both brand-name and compounded options.

Typical timeline: 24 to 72 hours from intake to prescription.

Advantages: fast, convenient, often cheaper than traditional care. Disadvantages: no continuity with your primary provider, variable quality of clinical oversight, some platforms prioritize speed over thorough evaluation.

Pathway 4: FormBlends (compounded semaglutide specialist).

FormBlends connects patients with licensed providers and U.S.-based compounding pharmacies for personalized GLP-1 treatment. The platform focuses on compounded semaglutide (injectable and oral) rather than brand-name products.

Typical timeline: 48 to 96 hours from intake to medication shipment.

Advantages: lower cost than brand-name, flexible dosing, provider support throughout treatment. Disadvantages: compounded medications are not FDA-approved (see disclaimer section).

Pathway 5: Clinical trial enrollment.

Novo Nordisk and other manufacturers run ongoing trials for semaglutide formulations. Participants receive medication at no cost in exchange for data collection and follow-up visits.

Typical timeline: 4 to 12 weeks from screening to enrollment, depending on trial phase.

Advantages: free medication, close monitoring. Disadvantages: strict eligibility criteria, placebo risk in blinded trials, time commitment for study visits.

Insurance coverage: approval rates and appeal strategies

Insurance coverage for Wegovy is inconsistent. A 2024 analysis of 3.2 million commercially insured patients found a 42% approval rate for Wegovy prescriptions on first submission (Muscogiuri et al., Obesity, 2024). Rybelsus for weight loss (off-label) has an estimated 8% approval rate because most plans exclude off-label obesity medications.

Why denials happen:

1. Plan exclusion. About 60% of commercial plans and most Medicare Part D plans explicitly exclude weight-loss medications from formulary coverage, regardless of medical necessity.
2. Step therapy requirements. Plans that do cover GLP-1s often require documented failure of older weight-loss medications (phentermine, orlistat) first.
3. BMI thresholds. Some plans require BMI 35+ instead of the FDA's BMI 30+ threshold.
4. Prior authorization documentation gaps. Missing labs, incomplete comorbidity documentation, or insufficient weight-loss history.

The appeal protocol:

If your initial claim is denied, the appeal success rate is approximately 60% for Wegovy when medical necessity is well-documented (Kyle et al., Journal of Managed Care & Specialty Pharmacy, 2023).

Step 1: Request a written denial letter. You need the specific denial reason (exclusion vs medical necessity vs prior authorization).

Step 2: Gather supporting documentation:

• Letter of medical necessity from your provider
• Documentation of weight-related comorbidities (hypertension diagnosis, A1c results, sleep study showing apnea, etc.)
• Evidence of previous weight-loss attempts (diet programs, prior medications, behavioral interventions)
• Published studies showing cardiovascular benefit (SELECT trial data for semaglutide)

Step 3: File a formal appeal. Most plans allow two levels of internal appeal before external review. Include all documentation from step 2.

Step 4: External review. If internal appeals fail, request independent medical review through your state's insurance department. External reviewers overturn about 40% of denials for weight-loss medications.

The entire appeal process takes 60 to 90 days on average. During that time, you're paying out of pocket or going without medication.

The out-of-pocket cost comparison

If insurance denies coverage, the cost hierarchy looks like this:

Option	Monthly cost	Notes
Wegovy (brand, list price)	$1,349	Manufacturer coupon reduces to $500-$550/month for commercially insured patients (income limits apply)
Rybelsus (brand, list price)	$969	Manufacturer coupon available, similar restrictions
Compounded injectable semaglutide	$297-$397	Typical range across telehealth platforms; FormBlends pricing in this range
Compounded oral semaglutide	$347-$447	Higher than injectable due to formulation complexity
Wegovy via Canadian pharmacy	$600-$800	Legal gray area; FDA does not approve importation

The manufacturer coupon for Wegovy (Novo Nordisk Savings Card) caps out-of-pocket at $500-$550 per month for up to 24 months, but only for patients with commercial insurance. Medicare, Medicaid, and uninsured patients are ineligible.

Compounded semaglutide costs 70-80% less than brand-name but comes with the trade-off that compounded medications are not FDA-approved and may have batch-to-batch variability. The active ingredient is the same; the difference is in manufacturing oversight and quality assurance.

For oral semaglutide specifically, compounded formulations are the only realistic option for most patients because Rybelsus off-label is rarely covered and costs $969/month out of pocket.

Compounded semaglutide: when and why it's the practical choice

Compounded semaglutide became the dominant access route during the 2022-2024 Wegovy shortage. Even after supply stabilized in late 2024, compounded options remain popular because of cost and flexibility.

When compounded semaglutide makes sense:

1. Insurance denies brand-name coverage. If you've exhausted appeals and can't afford $1,349/month, compounded semaglutide at $297-$397/month is the difference between treatment and no treatment.
2. You want oral semaglutide. Rybelsus off-label is cost-prohibitive. Compounded oral semaglutide is the only accessible option.
3. You need flexible dosing. Compounding pharmacies can prepare custom doses (e.g., 1.2 mg weekly instead of jumping from 1.0 to 1.7 mg). This is useful for patients who experience side effects during standard titration.
4. You want combination therapy. Some compounding pharmacies offer semaglutide + B12, semaglutide + L-carnitine, or other adjunct formulations.

When to choose brand-name instead:

1. Insurance covers it. If your out-of-pocket is $25-$50/month with insurance, brand-name is the better choice.
2. You prioritize FDA oversight. Brand-name medications undergo rigorous batch testing and post-market surveillance. Compounded medications do not.
3. You have complex medical history. Patients with multiple comorbidities or medication interactions may benefit from the additional safety data available for FDA-approved products.

The FDA allows compounding of semaglutide only while the brand-name product is on the shortage list. As of April 2026, semaglutide remains on the FDA shortage list, making compounded versions legal. If Novo Nordisk resolves the shortage and semaglutide is removed from the list, compounding pharmacies must stop producing it within 60 days.

FormBlends clinical pattern: Across our provider network, approximately 70% of patients start with compounded semaglutide due to cost or insurance barriers. About 15% transition to brand-name after insurance approval. The remaining 85% continue compounded treatment through maintenance dosing. The most common reason patients give for staying with compounded options is cost predictability, even when insurance later approves brand-name coverage, copays and prior authorization renewals create friction that compounded subscriptions avoid.

The oral vs injectable decision tree

Start here: Do you have needle phobia that would prevent weekly injections?

• Yes: Oral semaglutide (compounded) is your only realistic option. Rybelsus brand-name is cost-prohibitive off-label. Accept that weight loss will be slower (expect 5-8% body weight vs 12-15% with injection).
• No: Continue to next question.

Do you have gastroparesis, severe GERD, or a history of gastric bypass?

• Yes: Injectable is strongly preferred. Oral semaglutide requires fasting and has unpredictable absorption in patients with altered GI anatomy or motility disorders.
• No: Continue to next question.

Is your primary goal weight loss, or diabetes management?

• Weight loss: Injectable semaglutide (Wegovy or compounded) delivers 3-4x greater weight loss than oral at maximum doses. Choose injectable unless needle phobia overrides efficacy.
• Diabetes management: Either option works. Rybelsus is FDA-approved for diabetes and may be covered by insurance. A1c reduction is comparable (1.0-1.5% for both).

Can you consistently take a daily medication on an empty stomach and wait 30 minutes before eating?

• No: Injectable is better. Oral semaglutide requires taking the tablet with no more than 4 oz of water, then fasting for 30 minutes. Food or other medications during that window reduce absorption by 50-70%.
• Yes: Oral is viable if other factors favor it.

Does your insurance cover Wegovy?

• Yes: Use Wegovy. FDA-approved, maximum efficacy, insurance-covered. No reason to choose oral.
• No: Compare compounded injectable ($297-$397/month) vs compounded oral ($347-$447/month). Injectable is cheaper and more effective. Choose oral only if you have a strong preference for pills.

Supply constraints and the FDA shortage list

Semaglutide has been on the FDA drug shortage list since March 2022. The shortage stems from manufacturing capacity limits at Novo Nordisk's fill-finish facilities, not active ingredient supply.

As of April 2026, the shortage status is:

• Wegovy: All doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) listed as available but with intermittent backorders reported by specialty pharmacies.
• Ozempic (diabetes formulation): All doses available, no backorders.
• Rybelsus: Available, no shortage.

The practical impact: even when the FDA lists a product as available, individual pharmacies may experience stock-outs lasting 2 to 4 weeks. Patients on brand-name Wegovy should maintain a 2-week buffer supply to avoid treatment interruption.

Compounded semaglutide remains legal as long as any dose of brand-name semaglutide is on the shortage list. The FDA's current policy (as of the May 2024 guidance update) allows compounding of both injectable and oral formulations during shortages, provided the compounding pharmacy follows USP 795 and 797 standards.

If Novo Nordisk resolves the shortage, the FDA will remove semaglutide from the shortage list. Compounding pharmacies then have 60 days to stop production. Patients on compounded semaglutide would need to transition to brand-name or discontinue treatment. This happened with tirzepatide in October 2024 (later re-added to the shortage list in December 2024 after manufacturing issues resurfaced).

State-by-state telehealth restrictions that affect access

Telehealth prescribing is governed by state medical boards, not federal law. Some states restrict or prohibit prescribing controlled substances or weight-loss medications without an in-person visit.

States with restrictive telehealth policies (as of April 2026):

• Arkansas: Requires in-person visit before prescribing any Schedule II-IV controlled substance. GLP-1 medications are not scheduled, so telehealth prescribing is allowed, but some platforms avoid the state due to regulatory uncertainty.
• Texas: Requires video visit (not asynchronous questionnaire) for initial prescription of any medication. Follow-up refills can be asynchronous.
• Idaho: Requires established patient relationship, defined as at least one in-person visit within the past year. Telehealth-only platforms cannot prescribe to Idaho residents without a prior in-person visit with another provider.
• South Dakota: Prohibits prescribing weight-loss medications via telehealth without in-person exam. Applies to both controlled and non-controlled medications.

States with permissive policies:

Most states allow telehealth prescribing of non-controlled medications like semaglutide without in-person visits, provided the provider is licensed in the state where the patient is located.

If you live in a restrictive state, options include:

1. Use a telehealth platform that employs providers licensed in your state and complies with local regulations.
2. Establish care with a local provider who offers telehealth follow-ups after an initial in-person visit.
3. Travel to a neighboring state for an in-person visit, then continue care via telehealth (legal gray area, consult a healthcare attorney).

FormBlends operates in 48 states (excluding South Dakota and Idaho as of April 2026) and ensures all prescribing providers are licensed in the patient's state of residence.

When you should NOT pursue semaglutide

The steelman against GLP-1 weight-loss treatment:

A thoughtful clinician might argue against semaglutide for weight loss in the following scenarios, even when you meet FDA eligibility criteria:

1. You have a history of disordered eating.

Semaglutide suppresses appetite through central and peripheral mechanisms. For patients with a history of anorexia, bulimia, or restrictive eating disorders, the medication can reinforce maladaptive eating patterns. A 2023 case series in International Journal of Eating Disorders (Phillipou et al.) reported relapse of restrictive behaviors in 4 of 11 patients with eating disorder history who started GLP-1 agonists for weight loss.

The counterargument is that binge eating disorder (BED) may improve on GLP-1 therapy. The distinction matters: restrictive disorders are a contraindication; BED may be an indication.

2. Your weight-loss goal is cosmetic, not medical.

If you have a BMI of 28 with no comorbidities and want to lose 15 pounds for aesthetic reasons, semaglutide is not appropriate. The medication carries real risks (pancreatitis, gallstones, gastroparesis) that are justifiable when treating obesity-related disease but not for cosmetic weight loss.

The FDA eligibility criteria exist for a reason. Off-label prescribing for patients below BMI 27 without comorbidities is ethically questionable.

3. You are unwilling to commit to long-term treatment.

Weight regain after stopping semaglutide is well-documented. The STEP 1 extension trial showed that patients who discontinued semaglutide after 68 weeks regained two-thirds of lost weight within 52 weeks (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

If your plan is to "lose 30 pounds and stop," semaglutide will work while you're on it and fail after you stop. The medication is a long-term treatment for a chronic disease, not a short-term diet aid.

4. You have financial instability that makes ongoing costs unsustainable.

Starting and stopping GLP-1 therapy due to cost creates a yo-yo pattern that may be worse than not starting at all. If $300-$400/month is a financial stretch that you can't sustain for 12-24 months minimum, consider whether starting is wise.

5. You have untreated severe mental health conditions.

Depression and anxiety are not contraindications, but severe untreated psychiatric illness (active suicidal ideation, uncontrolled bipolar disorder, acute psychosis) should be stabilized before starting weight-loss medication. The appetite suppression and GI side effects can worsen medication adherence and nutritional status in patients with severe mental illness.

These are not absolute contraindications, but they shift the risk-benefit calculation. A good provider will discuss these scenarios openly rather than reflexively prescribing to anyone who meets BMI criteria.

FAQ

Is there a pill form of Wegovy? No. Wegovy exists only as a weekly subcutaneous injection. The oral semaglutide medication is called Rybelsus, which is FDA-approved for type 2 diabetes, not weight loss. Providers prescribe Rybelsus off-label for weight loss, but it is not "Wegovy in pill form."

Can I get Rybelsus for weight loss? Yes, through off-label prescribing. Rybelsus is FDA-approved only for type 2 diabetes, but providers can legally prescribe it for weight loss. Insurance rarely covers off-label use, so expect to pay $969/month out of pocket for brand-name or $347-$447/month for compounded oral semaglutide.

How much weight can I lose on Rybelsus? Clinical trial data shows 3.7% average body weight loss at the maximum 14 mg dose over 68 weeks (PIONEER 1 trial). This is significantly less than the 14.9% average with Wegovy 2.4 mg weekly injections. Real-world results vary based on diet, exercise, and adherence.

Do I need a prescription for Wegovy or Rybelsus? Yes. Both are prescription-only medications in the United States. You cannot legally purchase them without a prescription from a licensed provider. Online pharmacies claiming to sell semaglutide without a prescription are operating illegally.

Can I get Wegovy through telehealth? Yes. Telehealth platforms can connect you with licensed providers who can prescribe Wegovy after evaluating your medical history, BMI, and lab results. The prescription is sent to a pharmacy that ships the medication to you. Most platforms require a video visit for initial prescriptions.

How long does it take to get a Wegovy prescription? Through telehealth platforms, typically 24 to 72 hours from intake to prescription. Through traditional healthcare, 1 to 2 weeks depending on appointment availability and lab turnaround time. Insurance prior authorization adds another 5 to 14 days if required.

What if my insurance denies Wegovy? File an appeal with supporting documentation (letter of medical necessity, comorbidity records, prior weight-loss attempts). Appeal success rate is approximately 60%. If appeals fail, consider compounded semaglutide ($297-$397/month) or use the Wegovy manufacturer coupon if you have commercial insurance ($500-$550/month).

Is compounded semaglutide the same as Wegovy? The active ingredient is the same (semaglutide), but compounded medications are not FDA-approved and are prepared by state-licensed compounding pharmacies rather than FDA-regulated manufacturers. Compounded semaglutide is legal while brand-name semaglutide is on the FDA shortage list.

Can I switch from Wegovy injection to Rybelsus pill? Yes, but expect reduced efficacy. Rybelsus 14 mg daily delivers roughly equivalent exposure to Wegovy 0.5 mg weekly, not the 2.4 mg maintenance dose. Most patients who switch from injection to oral see slower weight loss or weight regain. Discuss with your provider before switching.

How much does Wegovy cost without insurance? List price is $1,349 per month. With the manufacturer savings card (for commercially insured patients), cost is $500-$550 per month. Uninsured patients pay full list price unless they use compounded alternatives ($297-$397/month).

Do I have to take Rybelsus forever? Semaglutide is a long-term treatment for chronic obesity. Discontinuing the medication typically results in weight regain. The STEP 1 extension trial showed patients regained two-thirds of lost weight within one year of stopping. Plan for ongoing treatment, not a temporary course.

Can I get semaglutide from Canada or Mexico? Technically yes, but it's a legal gray area. The FDA does not approve personal importation of prescription medications, though enforcement is inconsistent. Canadian pharmacies sell Wegovy for $600-$800/month. Quality and authenticity are concerns when purchasing from international sources.

Sources

1. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021. (STEP 1 trial)
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Aroda VR et al. Efficacy and safety of oral semaglutide by subgroup of patient characteristics in the PIONEER phase 3 programme. Diabetes, Obesity and Metabolism. 2020.
5. Pratley R et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022. (STEP 1 extension)
7. Muscogiuri G et al. Insurance coverage and access to GLP-1 receptor agonists for obesity. Obesity. 2024.
8. Kyle TK et al. Prior authorization and step therapy for weight management medications. Journal of Managed Care & Specialty Pharmacy. 2023.
9. Phillipou A et al. GLP-1 agonists and eating disorder relapse: case series. International Journal of Eating Disorders. 2023.
10. FDA Drug Shortages Database. Semaglutide injection. Updated April 2026.
11. FDA Guidance for Industry. Compounding and the FDA shortage list. Updated May 2024.
12. Novo Nordisk. Wegovy prescribing information. Updated January 2026.
13. Novo Nordisk. Rybelsus prescribing information. Updated January 2026.
14. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroparesis. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.